Lower respiratory tract infections, Upper respiratory tract infections, Urinary tract infections including gonorrhoea, cystitis, Skin & soft tissue infections, Gynecological infections, Acute otitis media, Childhood infections.
3rd Generation Cephalosporin; AntimcrobiaI
Cefpodoxime is an oral 3rd generation cephalosporin, which has good stability to beta lactamases and activity against Gram negative and Gram positive bacteria. It is indicated for the treatment of infections either before the infecting organism has been identified. It is a prodrug its active metabolite is Cefpodoxime. Approximately 29 to 33% of Cefpodoxime excreted unchanged in the urine in 12 hours.
Cefpodoxime is indicated for the treatment of patients infected with susceptible strains of microorganisms which include a wide range of gram-positive & gram-negative bacteria. As it is highly stable in presence of β-lactamase enzyme, so it is more effective against gram-positive bacteria than other 3rd generation oral cephalosporins. The susceptible organisms include gram-positive bacteria eg. S. aureus (including penicillinase producing strains), S. saprophyticus, S. pneumoniae, S. pyogenes, S. agalactiae, P. magnus and gram-negative bacteria eg. E. coli, K. pneumoniae, H. influenzae (including β-lactamase producer & Ampicillin resistant strains), M. catarrhalis, N. gonorrhoeae (including penicillinase producing strains), P. mirabilis, C. diversus, H. parainfluenzae, K. oxytoca, P. vulgaris, P. rettgeri.
Adults (Including age 13 years & older): Acute community-acquired pneumonia: 400 mg / 200 mg 12 hourly 14 days. Acute bacterial exacerbation of chronic bronchitis: 400 mg / 200 mg 12 hourly 10 days. Uncomplicated gonorrhea (men/women): 200 mg Single dose. Rectal gonococcal infection in women: 200 mg Single dose. Skin & soft tissue infections: 200 mg twice days. Pharyngitis and/or tonsillitis: 200 mg 12 hourly 5-10 days. Uncomplicated urinary tract infection: 200 mg 12 hourly 7 days Acute maxillary sinusitis: 400 mg/200 mg 12 hourly 10 days Child: 15 days-6 months : 4 mg/kg every 12 hours, 6 months-2 years : 40 mg every 12 hours, 3-8 years: 80 mg every 12 hours, Over 9 years : 100 mg every 12 hours.
Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminium hydroxide) or H 2 blockers reduce peak plasma level by 24% to 42% and the extent of absorption by 27% to 32%, respectively.
Probenecid: Renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC.
Nephrotoxic drugs: Close monitoring of renal function is advised when Cefpodoxime Proxetil is administered concomitantly with compounds of known nephrotoxic potential.
Known allergy to the cephalosporin class of antibiotics. In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced because high & prolonged serum antibiotic concentration can occur in such individuals following usual doses. As with other antibiotics, prolonged use of Cefpodoxime may result in overgrowth of nonsusceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.
Gastrointestinal disorders (such as diarrhoea, nausea, vomiting & abdominal pain), rash, urticaria & itching.
Pregnancy Category B. Cefpodoxime is excreted in breast milk & caution should be exercised when administered to a nursing women.
Keep in a dry place away from light and heat. Keep out of the reach of children.
.png&w=384&q=75)